Morgan Stanley Ngm Biopharmaceuticals Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$1.17 - $1.92 $181,890 - $298,487	155,462 New	155,462 $247,000
Q1 2024 Aug 16, 2024	SELL	$1.17 - $1.92 $5,848 - $9,598	-4,999 Reduced 3.12%	155,462 $247,000
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $5,848 - $9,598	-4,999 Reduced 3.12%	155,462 $247,000
Q4 2023 Aug 16, 2024	BUY	$0.6 - $1.31 $96,276 - $210,203	160,461 New	160,461 $137,000
Q4 2023 Feb 13, 2024	SELL	$0.6 - $1.31 $190,067 - $414,980	-316,779 Reduced 66.38%	160,461 $137,000
Q3 2023 Nov 15, 2023	SELL	$1.05 - $3.37 $441,936 - $1.42 Million	-420,892 Reduced 46.86%	477,240 $510,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $102,048 - $189,458	41,823 Added 4.88%	898,132 $2.33 Million
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $722,706 - $1.05 Million	194,276 Added 29.35%	856,309 $3.49 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $392,061 - $1.49 Million	114,974 Added 21.02%	662,033 $3.32 Million
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $556,037 - $780,395	-44,165 Reduced 7.47%	547,059 $7.16 Million
Q2 2022 Oct 27, 2022	BUY	$10.58 - $17.5 $111,301 - $184,100	10,520 Added 1.81%	591,224 $7.58 Million
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $111,301 - $184,100	10,520 Added 1.81%	591,224 $7.58 Million
Q1 2022 Oct 27, 2022	SELL	$13.81 - $18.6 $145,281 - $195,672	-10,520 Reduced 1.78%	580,704 $8.86 Million
Q1 2022 May 13, 2022	BUY	$13.81 - $18.6 $3.96 Million - $5.33 Million	286,737 Added 97.54%	580,704 $8.86 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $2.61 Million - $3.33 Million	151,219 Added 105.93%	293,967 $5.21 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $2.88 Million - $3.74 Million	142,748 New	142,748 $3 Million

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account